Project Grant HT94252310266

This Project Grant award of $635,173 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to characterize the immune cell recruitment and immunosuppression mechanisms driven by the CKLF1 chemokine in MYCN-driven neuroblastoma. The award will leverage the zebrafish neuroblastoma model, patient sample analyses, in vitro co-culture systems, and mouse models to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $702,748 to Weill Medical College of Cornell University to research the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer immunotherapies. The key objectives are to: 1) characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, 2) identify the clinically...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286), provides $1,024,543.00 to the Regents of the University of Michigan to investigate nanoparticle strategies for reprogramming innate immune cells and disrupting the metastatic niche in triple negative breast cancer. The research aims to develop...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $5,666,172 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University (NYU) to conduct research on targeting Schwann cell dysfunction and repair signaling in chemotherapy-induced painful peripheral neuropathy (CIPPN). The research aims to study the role of the peroxisome proliferator activated receptor gamma (PPARG) and low-density lipoprotein receptor related protein 1 (LRP1)...

This $431,968 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Baylor College of Medicine to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression, and to modulate this metabolic environment to enhance immune-based approaches for high-risk MYCN-amplified neuroblastoma. The research aims to uncover how MYCN amplification, a driver of aggressive neuroblastoma,...

The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $628,373 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on understanding how endogenous dendritic cells drive T cell activation and expansion in glioblastoma. The award period runs from August 1, 2025 to June 30,...

This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...

This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports innovative research to enhance regulatory immune cell function and extend kidney allograft survival in non-human primates. The $1,455,073 award to the University of Pittsburgh aims to develop new agents and technologies that selectively promote dendritic cell tolerogenicity and regulatory T cell function, with the goal...